Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus

Endocrinology

Volumn 147, Issue 6, 2006, Pages 2619-2630

  Pennisi, Patricia ^a   Gavrilova, Oksana ^a   Setser Portas, Jennifer ^a   Jou, William ^a   Santopietro, Stefania ^a   Clemmons, David ^b   Yakar, Shoshana ^a   LeRoith, Derek ^a,c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; GLUTAMINE; PYRUVIC ACID; RECOMBINANT SOMATOMEDIN C; SODIUM CHLORIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY COMPOSITION; BODY FAT DISTRIBUTION; BODY WEIGHT; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; FATTY ACID BLOOD LEVEL; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; KIDNEY; LEAN BODY WEIGHT; LIVER; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SKELETAL MUSCLE; SMALL INTESTINE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRINKING; GLUCONEOGENESIS; GLUCOSE CLAMP TECHNIQUE; GLUCOSE-6-PHOSPHATASE; GROWTH HORMONE; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; INTESTINE, SMALL; KIDNEY; LIVER; MALE; MICE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); RECOMBINANT PROTEINS;

EID: 33646810078     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-1556     Document Type: Article

References (53)

1. Froesch ER, Hussain MA, Schmid C, Zapf J 1996 Insulin-like growth factor I: physiology, metabolic effects and clinical uses. Diabetes Metab Rev 12:195-215
2. Rajaram S, Baylink DJ, Mohan S 1997 Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 18:801-831
3. Federici M, Porzio O, Zucaro L, Giovannone B, Borboni P, Marini MA, Lauro D, Sesti G 1997 Increased abundance of insulin/IGF-I hybrid receptors in adipose tissue from NIDDM patients. Mol Cell Endocrinol 135:41-47
4. Zapf J, Schoenle E, Waldvogel M, Sand I, Froesch ER 1981 Effect of trypsin treatment of rat adipocytes on biological effects and binding of insulin and insulin-like growth factors: further evidence for the action of insulin-like growth factors through the insulin receptor. Eur J Biochem 113:605-609
5. Walker JL, Van Wyk JJ, Underwood LE 1992 Stimulation of statural growth by recombinant insulin-like growth factor I in a child with growth hormone insensitivity syndrome (Laron type). J Pediatr 121:641-646
6. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR 1993 Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest 91:391-396
7. Cheetham TD, Holly JM, Baxter RC, Meadows K, Jones J, Taylor AM, Dunger DB 1998 The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 157:81-87
8. Clemmons DR, Moses AC, Sommer A, Jacobson W, Rogol AD, Sleevi MR, Allan G 2005 Rh/IGF-I/rhIGFBP-3 administration to patients with type 2 diabetes mellitus reduces insulin requirements while also lowering fasting glucose. Growth Horm IGF Res 15:265-274
9. Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J 2000 The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity. J Clin Endocrinol Metab 85:1518-1524
10. Cusi K, DeFronzo R 2000 Recombinant human insulin-like growth factor I treatment for 1 week improves metabolic control in type 2 diabetes by ameliorating hepatic and muscle insulin resistance. J Clin Endocrinol Metab 85:3077-3084
11. Moses AC, Young SC, Morrow LA, O'Brien M, Clemmons DR 1996 Recombinant human insulin-like growth factor I increases insulin sensitivity and improves glycemic control in type II diabetes. Diabetes 45:91-100
12. Carroll PV, Umpleby M, Ward GS Imuere S, Alexander E, Dunger D, Sonksen PH, Russell-Jones DL 1997 rhIGF-I administration reduces insulin requirements, decreases growth hormone secretion, and improves the lipid profile in adults with IDDM. Diabetes 46:1453-1458
13. Guler HP, Zapf J, Froesch ER 1987 Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med 317:137-140
14. Schmitz F, Hartmann H, Stumpel F, Creutzfeldt W 1991 In vivo metabolic action of insulin-like growth factor I in adult rats. Diabetologia 34:144-149
15. Dimitriadis G, Parry-Billings M, Bevan S, Dunger D, Piva T, Krause U, Wegener G, Newsholme EA 1992 Effects of insulin-like growth factor I on the rates of glucose transport and utilization in rat skeletal muscle in vitro. Biochem J 285(Pt 1):269-274
16. Poggi C, Le Marchand-Brustel Y, Zapf J, Froesch ER, Freychet P 1979 Effects and binding of insulin-like growth factor I in the isolated soleus muscle of lean and obese mice: comparison with insulin. Endocrinology 105:723-730
17. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143-163
18. Zenobi PD, Jaeggi-Groisman SE, Riesen WF, Roder ME, Froesch ER 1992 Insulin-like growth factor-I improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest 90:2234-2241
19. Morrow LA, O'Brien MB, Moller DE, Flier JS, Moses AC 1994 Recombinant human insulin-like growth factor-I therapy improves glycemic control and insulin action in the type A syndrome of severe insulin resistance. J Clin Endocrinol Metab 79:205-210
20. Moses AC, Morrow LA, O'Brien M, Moller DE, Flier JS 1995 Insulin-like growth factor I (rhIGF-I) as a therapeutic agent for hyperinsulinemic insulin-resistant diabetes mellitus. Diabetes Res Clin Pract 28(Suppl):S185-S194
21. Frick F, Oscarsson J, Vikman-Adolfsson K, Ottosson M, Yoshida N, Eden S 2000 Different effects of IGF-I on insulin-stimulated glucose uptake in adipose tissue and skeletal muscle. Am J Physiol Endocrinol Metab 278:E729-E737
22. Fernandez AM, Kim JK, Yakar S, Dupont J, Hernandez-Sanchez C, Castle AL, Filmore J, Shulman GI, Le Roith D 2001 Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev 15:1926-1934
23. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D 2002 Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest 110:771-781
24. Kim JK, Gavrilova O, Chen Y, Reitman ML, Shulman GI 2000 Mechanism of insulin resistance in A-ZIP/F-1 fatless mice. J Biol Chem 275:8456-8460
25. MacLeod JN, Shapiro BH 1988 Repetitive blood sampling in unrestrained and unstressed mice using a chronic indwelling right atrial catheterization apparatus. Lab Anim Sci 38:603-608
26. Hirsch J, Gallian E 1968 Methods for the determination of adipose cell size in man and animals. J Lipid Res 9:110-119
27. Zhao H, Yakar S, Gavrilova O, Sun H, Zhang Y, Kim H, Setser J, Jou W, LeRoith D 2004 Phloridzin improves hyperglycemia but not hepatic insulin resistance in a transgenic mouse model of type 2 diabetes. Diabetes 53:2901-2909
28. Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D 2003 Peroxisome proliferator-activated receptor-α agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes 52:1770-1778
29. Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB 1998 Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 47:1481-1489
30. Jacob RJ, Sherwin RS, Bowen L, Fryburg D, Fagin KD, Tamborlane WV, Shulman GI 1991 Metabolic effects of IGF-I and insulin in spontaneously diabetic BB/w rats. Am J Physiol 260:E262-E268
31. Kim H, Barton E, Muja N, Yakar S, Pennisi P, Leroith D 2005 Intact insulin and insulin-like growth factor-I receptor signaling is required for growth hormone effects on skeletal muscle growth and function in vivo. Endocrinology 146:1772-1779
32. Gerich JE, Meyer C, Woerle HJ, Stumvoll M 2001 Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 24:382-391
33. Stumvoll M, Perriello G, Meyer C, Gerich J 1999 Role of glutamine in human carbohydrate metabolism in kidney and other tissues. Kidney Int 55:778-792
34. Mithieux G, Rajas F, Gautier-Stein A 2004 A novel role for glucose 6-phosphatase in the small intestine in the control of glucose homeostasis. J Biol Chem 279:44231-44234
35. Stumvoll M, Meyer C, Perriello G, Kreider M, Welle S, Gerich J 1998 Human kidney and liver gluconeogenesis: evidence for organ substrate selectivity. Am J Physiol 274:E817-E826
36. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, Chernausek SD, Mejia W, Le Roith D 2001 Liver-specific IGF-I gene deletion leads to muscle insulin insensitivity. Diabetes 50:1110-1118
37. Turkalj I, Keller U, Ninnis R, Vosmeer S, Stauffacher W 1992 Effect of increasing doses of recombinant human insulin-like growth factor-I on glucose, lipid, and leucine metabolism in man. J Clin Endocrinol Metab 75:1186-1191
38. Laager R, Ninnis R, Keller U 1993 Comparison of the effects of recombinant human insulin-like growth factor-I and insulin on glucose and leucine kinetics in humans. J Clin Invest 92:1903-1909
39. Mauras N, Beaufrere B 1995 Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab 80:869-874
40. Caro JF, Poulos J, Ittoop O, Pories WJ, Flickinger EG, Sinha MK 1988 Insulin-like growth factor I binding in hepatocytes from human liver, human hepatoma, and normal, regenerating, and fetal rat liver. J Clin Invest 81:976-981
41. Pennisi PA, Kopchick JJ, Thorgeirsson S, LeRoith D, Yakar S 2004 Role of growth hormone (GH) in liver regeneration. Endocrinology 145:4748-4755
42. Clemmons DR 1997 Insulin-like growth factor binding proteins and their role in controlling IGF actions. Cytokine Growth Factor Rev 8:45-62
43. Federici M, Zucaro L, Porzio O, Massoud R, Borboni P, Lauro D, Sesti G 1996 Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. J Clin Invest 98:2887-2893
44. LeRoith D 2002 β-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities. Am J Med 113(Suppl 6A):3S-11S
45. Robertson RP, Harmon J, Tran PO, Tanaka Y, Takahashi H 2003 Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52:581-587
46. Pratipanawatr T, Pratipanawatr W, Rosen C, Berria R, Bajaj M, Cusi K, Mandarino L, Kashyap S, Belfort R, DeFronzo RA 2002 Effect of IGF-I on FFA and glucose metabolism in control and type 2 diabetic subjects. Am J Physiol Endocrinol Metab 282:E1360-E1368
47. Boulware SD, Tamborlane WV, Rennert NJ, Gesundheit N, Sherwin RS 1994 Comparison of the metabolic effects of recombinant human insulin-like growth factor-I and insulin. Dose-response relationships in healthy young and middle-aged adults. J Clin Invest 93:1131-1139
48. Fernandez AM, Dupont J, Farrar RP, Lee S, Stannard B, Le Roith D 2002 Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest 109:347-355
49. Radziuk J, Pye S 2001 Hepatic glucose uptake, gluconeogenesis and the regulation of glycogen synthesis. Diabetes Metab Res Rev 17:250-272
50. Petersen KF, Price T, Cline GW, Rothman DL, Shulman GI 1996 Contribution of net hepatic glycogenolysis to glucose production during the early post-prandial period. Am J Physiol 270:E186-E191
51. Chandramouli V, Ekberg K, Schumann WC, Kalhan SC, Wahren J, Landau BR 1997 Quantifying gluconeogenesis during fasting. Am J Physiol 273:E1209-E1215
52. Mithieux G, Vidal H, Zitoun C, Bruni N, Daniele N, Minassian C 1996 Glucose-6-phosphatase mRNA and activity are increased to the same extent in kidney and liver of diabetic rats. Diabetes 45:891-896
53. Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J 1998 Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102:619-624